HBM BioVentures invests in the drugs and healthcare technology of tomorrow.

HBM BioVentures is an attractive alternative to investments in large pharmaceutical and biotech corporations.

HBM BioVentures enables the development of promising new biotechnologies.

Successful Initial Public Offering of ChemoCentryx increases HBM BioVentures net asset value (NAV) by CHF 1.06 (+1.9%)per share.